AUTL Autolus Therapeutics plc

12.57
+0.07  (+1%)
Previous Close 12.5
Open 12.67
Price To Book 1.9
Market Cap 565,421,980
Shares 44,981,860
Volume 12,720
Short Ratio
Av. Daily Volume 366,640

NewsSee all news

  1. Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

    Findings from Phase I CARPALL Trial Demonstrate that Autolus' Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a

  2. Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

    LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data due 2020.
AUTO4
T-cell lymphoma
Phase 1 interim data due at ASH 2019. Phase 2 decision on initiation in DLBCL is expected in mid-2020
AUTO3 - (ALEXANDER)
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1 data due at ASH 2019.
AUTO2
Relapsed or refractory multiple myeloma
Phase 2 trial to be initiated 2H 2019. Updated Phase 1 data due at ASH 2019.
AUTO1
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Phase 1 data due at ASH 2019.
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia
Phase 1/2 trial to be initiated 2H 2020.
AUTO6
Neuroblastoma

Latest News

  1. Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

    Findings from Phase I CARPALL Trial Demonstrate that Autolus' Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a

  2. Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

    LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will